Introduction
Stroke is a common condition with an estimated yearly incidence for fi rst-ever occurrence of 1·65 per 1000 population. 1 Immediate admission to hospital for treatment and rehabilitation is recommended, however, most patients return home with some residual disability. 2 Substantial reliance and burden is placed on informal caregivers, usually family members, to provide assistance with activities of daily living, including dressing and toileting after hospital discharge, 3 which can aff ect caregivers' physical and psychosocial wellbeing. 4, 5 The economic value of the informal care provided is substantial. 6, 7 Eff ective interventions directed at care givers of patients who have had a stroke are important both to sustain their own health and to improve the recovery and adjustment of the patient who has had a stroke. 8, 9 A systematic, structured training programme for caregivers, delivered in a stroke unit, which included assessment of competencies in skills essential for the day-to-day management of disabled stroke survivors (the London Stroke Carers Training Course, LSCTC) was developed and assessed in a single-centre individually randomised trial. 10 Results from this trial 10 reported a decrease in caregiver burden, anxiety, and depression, improved psychological outcomes for patients, and reduced overall costs largely due to earlier hospital discharge following the LSCTC compared with usual care. 11 We established the training caregivers after stroke (TRACS) trial to investigate the wider generalisability of the LSCTC intervention and to assess the eff ectiveness of the LSCTC in improving physical outcomes for the patient and reducing caregiver burden.
Methods

Study design and participants
TRACS was a UK, pragmatic, multicentre cluster randomised trial of the LSCTC. We purposely selected the cluster randomised trial design to reduce betweengroup treatment contamination. Methods have been reported in detail elsewhere. 12 In summary, stroke units were eligible if: four of fi ve criteria used to defi ne a stroke unit were met; 13 a substantial number of patients on the unit had a diagnosis of stroke; staff were able to deliver the LSCTC; and most patients were discharged to a permanent place of residence. We also undertook an embedded process evaluation that will be reported separately.
In keeping with the pragmatic trial design, eligibility criteria were deliberately broad and inclusive. Patients were eligible for participation if they had a confi rmed primary diagnosis of new stroke (ischaemic or intracerebral haemorrhage; fi rst or recurrent stroke); were medically stable, likely to return home with residual disability; and, following discharge, had a caregiver available, willing and able to provide support. We defi ned the caregiver as the main person, other than health, social, or voluntary care provider, helping with activities of daily living or advocating on behalf of the patient. We excluded patient and caregiver dyads if the patient needed palliative care, discharge was planned within 1 week of admission to the stroke unit (insuffi cient time for exposure to the intervention), or the patient or caregiver was previously registered to the trial.
All participants provided written informed consent or assent for participation in the trial. The study protocol was approved by Leeds Research Ethics Committee (reference 07/Q1205/12), and accepted by The Lancet.
Randomisation and masking
Cluster randomisation was done centrally at the Clinical Trials Research Unit (CTRU). Stroke units were randomly assigned (1:1) to either the intervention group or the control group, stratifi ed by geographical region and quality of care (defi ned as being on and above or below the median on the key 12 indicator score of the 2006 National Sentinel Audit). 13 We used block randomisation (blocks of size 2) to ensure these important covariates were balanced between the arms of the trial.
Researchers independent of clinical teams delivering patient care undertook participant recruitment and collection of baseline data. We completed detailed screening logs throughout the trial to monitor for selection bias. Participants were masked to the stroke unit allocation.
Procedures
The LSCTC is a structured training programme for caregivers, which includes assessment of competencies in knowledge or skills essential for the day-to-day management of disabled survivors of stroke (for example, knowledge of stroke, handling skills for activities of daily living). The programme has 14 components, six components are mandatory, eight non-mandatory dependent on individual patient and caregiver needs (appendix). Caregivers' competency can be checked by observing the skill, or questioning their understanding. The LSCTC was modifi ed for national rollout by the multidisciplinary team who delivered the LSCTC in the single-centre study. 10 They developed an intervention manual and caregiver training record, and devised and delivered a training programme to members of the multidisciplinary team in intervention sites through centrally organised training days. Staff attending the training were tasked with cascading the LSCTC to other members of the multidisciplinary team and were provided with materials (slides and recordings of talks) to support them in doing so. Subsequently, staff were to gradually increase delivery of the LSCTC until it became an integral part of the ward care process. After the initial training meeting, intervention stroke units were given 4-6 months to implement the LSCTC into standard ward practice.
We used the caregiver training record to measure the intervention unit's compliance with LSCTC provision and to estimate its costs. The LSCTC developers agreed a defi nition of compliance as: indication on the training record that training on the six mandatory components had been delivered and competency achieved by the caregiver, or the record was signed off by a member of the multidisciplinary team indicating that all necessary training had been delivered and competency achieved.
Stroke units randomly assigned to the control group were asked to continue usual care as recommended in national guidelines. 14 Patient baseline data included: sex, age, ethnic origin, education, employment, living arrangements, relationship to caregiver, previous stroke, disability before stroke, date and type of stroke, test of cognition, 15 and language impairment. We collected the six components of the Edinburgh stroke casemix adjuster 16 to enable adjustment for stroke severity. For the caregiver, we recorded sex, age, ethnic origin, physical ability (modifi ed Rankin scale), education, and employment. We noted the incidence of falls between recruitment and discharge as an expected serious adverse event.
We recorded primary and secondary outcomes via self-completed questionnaires in hospital at baseline, and via postal questionnaires at 6 and 12 months. Where the patient was unable to complete the question naire independently, the caregiver could provide help or complete the questionnaire by proxy. We compared details of proxy completion between the two groups of the study. 
Statistical analysis
The primary outcome for patients was self-reported functional independence in extended activities of daily living (ADL) measured at 6 months after recruitment using the Nottingham Extended Activities of Daily Living (NEADL). 17, 18 The primary outcome for caregivers was selfreported burden using the caregivers burden scale (CBS) measured at 6 months. 19 Secondary outcomes for patients were self-reported versions of: the hospital anxiety and depression scale (HADS), EQ-5D and quality-adjusted life-years (QALYs) generated from it using societal weights, Barthel Index, and Stroke Impact Scale (SIS). [20] [21] [22] [23] Secondary outcomes for caregivers were self-report versions of Frenchay activities index, 24 HADS, and EQ-5D and QALYs generated from it. We used an adapted selfcomplete client service receipt inventory (CSRI) to measure patient and caregiver resource use (use of services before stroke and after discharge).
11, 25 We recorded patient and caregiver deaths, hospital readmissions, and institution alisations. We obtained process data before, during, and after recruitment at every participating stroke unit to monitor any changes in eligibility in stroke units and in the process of care that prepared patients and caregivers for discharge in those units.
We calculated that 36 stroke units, each recruiting 25 patients, resulting in 450 patients per group, would provide close to 90% power at 5% signifi cance level to detect a six-point diff erence on the NEADL, a diff erence agreed as clinically relevant. 26 The sample size incorporated an infl ation factor of 1·9 due to clustering (cluster size of 19 after loss to follow-up; intracluster correlation coeffi cient (ICC) no greater than 0·05) 27 and 25% loss to follow-up. The power of the trial was adversely aff ected by a higher than expected loss to follow-up and unequal cluster sizes. By estimating maximum and minimum cluster sizes the predicted imbalance decreased the power by 1-3%. To preserve fi nal power of 90%, we increased the trial sample size from 900 to 950 patient and caregiver dyads, allowing up to 35 dyads per stroke unit to compensate for lower recruitment at some centres.
We undertook analyses and data summaries on an intention-to-treat basis-we analysed all patients registered for active follow-up within a stroke unit according to the group that that stroke unit was randomly assigned to, regardless of non-compliance. We did all statistical testing at a 2-sided 5% signifi cance level.
Since the trial was cluster randomised, we compared the primary outcome measures, the 6-month NEADL score and the CBS, between the intervention and control groups using a two-level hierarchical model, with patients (or caregivers) nested within stroke units. We adjusted for patient-level baseline covariates (baseline NEADL, sex, caregiver's education, caregiver baseline HADS score, Edinburgh stroke casemix adjuster), and stroke unit-level covariates (geographical region, key 12 indicator score, and number of beds in every centre) in the model. We analysed secondary outcomes for patients and caregivers using similar multilevel models. We reported eff ect sizes, 95% CIs, and adjusted ICCs. We summarised death, hospital admission, and institution alisation by treatment group but undertook no formal statistical comparison between the intervention and control groups.
We did the analyses assuming data missing completely at random using complete cases. We used various sensitivity analyses to examine the robustness of the conclusions of the primary analysis, a sensitivity analysis including patients who had died (assuming a NEADL score of 0), a repeat of the primary analysis assuming data are missing at random, and a sensitivity analysis excluding proxy responses. A secondary analysis explored the relationship between outcome and com pliance with the LSCTC.
Economic evaluation
The prospective economic evaluation assessed the costeff ectiveness of the LSCTC for patients and caregivers at 6 months (appendix). We combined patient and caregiver health and social care service and societal costs with NEADL (patient), CBS (caregiver), and QALY outcomes. We attached unit costs to individual-level resource use quantities to calculate a cost per participant. We included the development and staff training costs associated with the LSCTC. We compared costs and QALYs and examined the probability of cost-eff ectiveness by constructing costeff ectiveness acceptability curves using threshold ranges of £0-2000 for point gains on the NEADL and CBS and £0-50 000 for QALY gains. This trial is registered with controlled-trials.com, number ISRCTN 49208824.
Role of the funding source
The trial was a major collaborative eff ort with colleagues in the National Institute for Health Research (NIHR) Stroke Research Network. The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication. AP had full access to the health economics data. AFa had full access to all the data and acts as statistical guarantor.
Results
36 UK stroke units in four geographical regions (Yorkshire, the North West, the South West Peninsula, and London and the southeast) were randomised in the trial. 49 stroke units in these regions expressed an interest in TRACS, 41 completed feasibility questionnaires, 39 were eligible, and 36 completed approval processes in time to be entered for randomisation (fi gure 1). Between Feb 27, 2008, and Feb 9, 2010, 12 510 patients and caregivers were screened, and 928 patient and caregiver dyads were registered in the trial (450 in the intervention group, 478 in the control group), 35% of the 2675 eligible patient and caregiver dyads (fi gure 1). The groups were well balanced at baseline (tables 1 and 2, appendix). There were more male patients than female patients in both groups. Caregivers were younger than patients, most caregivers had left education at age 16 years or younger, more women than men were acting as caregivers in both groups, and in most cases they were the patients' partner. The response rates for the endpoints at 6 and 12 months were: 690 (74%) of 928 patients at 6 months (335 patients in intervention group and 355 patients in control group) and 638 (69%) of 928 patients at 12 months (305 patients in intervention group and 333 patients in control group), and 673 (73%) of 928 caregivers at 6 months (329 caregivers in intervention group and 344 caregivers in control group) and 609 (66%) of 928 caregivers at 12 months (295 caregivers in intervention group and 314 caregivers in control group).
The patient primary outcome of the NEADL score at 6 months did not diff er signifi cantly between groups, neither did the caregiver primary outcome of the CBS at 6 months (table 3) . We also noted no diff erences in patient and caregiver secondary endpoints at 6 or 12 months (appendix). Sensitivity analyses done on the primary outcomes confi rmed the conclusions of the primary analyses (data not shown).
Average intervention compliance was 44% (196 of 450); half the participating centres had a compliance rating of more than 60%. 124 (28%) of 450 training records were not completed by the sites (appendix). Results from an exploratory analysis showed no relation between increased patient functional independence or lower caregiver burden in stroke units with greater intervention com pliance (appendix). Intervention delivery was not associated with increased risk of inpatient falls (50 in the intervention group vs 42 in the control group). The number of deaths, hospital readmissions, or institutionalisation rates did not diff er between the intervention and control groups at either 6 or 12 months after registration (data not shown). The process data revealed changes to inpatient care in just one centre; carer involvement was reduced in an intervention centre (data not shown).
The mean cost per patient of the LSCTC training and development was £82 in those receiving inputs and £39 when including zero costs for those either receiving no LSCTC inputs or with missing data regarding such inputs. The length of the initial stroke admission and associated costs were similar in both groups (£13 127 for the intervention group and £12 471 for the control group; adjusted mean diff erence £1243 [95% CI -1533 to 4019]; p=0·380). Total health and social care costs for patients and societal costs for patients or caregivers did not diff er between groups at 6 months, 12 months, or over 1 year (appendix). Caregivers in the intervention group had higher health and social care costs at 6 months (adjusted mean diff erence £207 [95% CI 5-408], p=0·045). This diff erence was no longer present at 12 months or over 1 year (appendix). We noted no evidence of signifi cant diff erences in QALYs for patients or caregivers at any assessment point (appendix). For the threshold ranges examined, probabilities of the cost-eff ectiveness of the LSCTC in the patient evaluation peaked at 51% based on the NEADL. In the caregiver evaluation, the probability of cost-eff ectiveness reached 62% from a health and social care perspective and 68% from a societal perspective based on the CBS, although it is unknown what the willingness to pay for a CBS point improvement would be in practice. From the health and social care perspective, probabilities of cost-eff ectiveness based on QALYs were low at a maximum of 36% in the patient evaluation and just 2% in the caregiver evaluation (fi gure 2). Thus the intervention is unlikely to be considered cost-eff ective within current policy thresholds of £20 000 to £30 000 per QALY gained.
Discussion
A Cochrane review of eight studies (n=1007) examined the eff ectiveness of non-pharmacological interventions for caregivers of stroke survivors in reducing caregiver burden or enhancing caregiver wellbeing. 28 The review concluded that previous studies have methodological limitations; further robust evaluation was required; and the eff ects of caregiver interventions on the patient also need to be assessed. The LSCTC was the most promising intervention reviewed. The TRACS trial was a pragmatic, multicentre, cluster randomised controlled trial of the LSCTC complex intervention. Patients who had had a stroke attending intervention stroke units did not show a clinically signifi cant improvement in functional independence compared with patients who had had a stroke attending the control stroke units at 6 months after registration. The burden for caregivers of patients attending intervention stroke units did not signifi cantly diff er with that of caregivers of patients attending the control stroke units at 6 months. Other physical and psychological outcomes did not diff er for patients and caregivers. Patient costs were similar and caregiver costs were higher in the intervention group, and the LSCTC is unlikely to be cost eff ective (panel).
The LSCTC was initially assessed in a single-centre individually randomised trial that reported a range of benefi ts. 10 That study involved a smaller cohort of patients and caregivers and was delivered by the multidisciplinary team who had developed the intervention and who might have had particular expertise and commitment. This expertise might not have been replicated in the range of stroke units who delivered the intervention in this trial. In the 10 years since the single-centre study, 10 stroke care might have improved in a way consistent with some of the LSCTC practices. However, our process evaluation indicates that it is unlikely that standard care has improved to such a degree that caregivers' needs have been successfully met (publication in preparation). It is possible that the immediate post-stroke period, when potential caregivers are coming to terms with their new situation, might not be the ideal time for the delivery of structured training. The intervention approach might be more relevant if delivered after discharge by communitybased teams.
The TRACS trial included stroke units from diff erent health-care settings (acute and community hospitals in rural and urban settings) in four disparate geographical regions. Eligibility criteria were purposely inclusive to ensure that a representative population of patients who have had a stroke was recruited. We were careful to choose outcomes that were known to be valid reliable and sensitive to change in this population. The numbers of participants and their baseline characteristics were well balanced between the study groups, demonstrating that selection bias was avoided. Loss of power caused by the unequal cluster sizes was compensated for by increasing recruitment beyond 900. The follow-up rate of 75% at 6 months required for the power calculation was nearly achieved. We are therefore confi dent that the TRACS trial results are robust and generalisable to all patients who have had a stroke and their informal caregivers in stroke units across the UK.
Panel: Research in context
Systematic Review A Cochrane review from 2011 28 has summarised the eff ectiveness of non-pharmacological interventions for caregivers of stroke survivors in reducing caregiver burden or enhancing caregiver wellbeing. 28 In eight randomised trials including 1007 participants, an intervention that focused on preparing participants for the work of caring for a stroke survivor (the LSCTC) was the most promising intervention. However, the evidence for this was from a single-centre randomised trial. 10 We searched the scientifi c literature before the publication of the Cochrane review 28 on the eff ectiveness of caregiver interventions, and we identifi ed no eff ective early training programmes for caregivers of patients after stroke, other than the LSCTC.
Interpretation
The purpose of TRACS was to assess if the LSCTC continued to show benefi ts to caregivers and patients who have had a stroke if implemented as a part of standard practice in stroke units across the UK. The TRACS trial (n=928) has almost doubled the sample size of the Cochrane Review, providing conclusive evidence that recovery of patients who have had a stroke, caregivers' burden, or other physical and psychological outcomes do not diff er between the LSCTC and usual care, nor is the LSCTC cost eff ective when compared with usual care. Caregivers need more than just an inpatient structured training programme to improve the patients' and their own outcomes.
In keeping with the pragmatic nature of the trial, the LSCTC intervention was implemented in accord with usual NHS practices for a new service initiative and used methods that would be acceptable and feasible to multidisciplinary teams and NHS management to allow widespread dissemination if eff ectiveness was proven. The intervention was acceptable to the staff attending the training days, with recognition of the importance of each of the core competencies, demonstrating face validity for the intervention. The intent was that the training was cascaded down by staff attending the training days to other ward colleagues. It might be that this commonly used cascade method was not as eff ective as we would have wished. A more intensive (but thus less pragmatic and more resource intensive) strategy to implement the intervention might have been more successful. A component of the intervention was the completion of the caregiver training record. Completed training records were returned to the Trial Manager and included as a standard monitoring report to the Trial Management Group and Trial Steering Committee. Half of the participating centres had a compliance rating of over 60%. Such a compliance rate is compatible with other trials assessing complex interventions in stroke rehabilitation. 29 Some units did not implement the LSCTC as robustly as envisaged, however, analyses of patient independence and caregiver burden showed no associations with levels of intervention compliance.
In conclusion, we have undertaken a robust multicentre, cluster randomised trial, showing that this method is feasible in stroke rehabilitation research. The intervention was associated with benefi ts in a singlecentre evaluation but these benefi ts have not been replicated in this large, pragmatic multicentre trial. There was no diff erence between the LSCTC and usual care with respect to improving functional independence of patients who have had a stroke, reducing caregivers' burden, or improving other physical and psychological outcomes, nor is it cost eff ective when compared with usual care. Caregivers need more than just an inpatient structured training programme to improve the patients' and their own outcomes. The integrated intervention approach might be more relevant, whereby initial hospital training is supported with follow-up training after discharge delivered by community-based teams.
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